Innovation Breakthrough of BCI DBS Technology: SceneRay Launched "SR1384 System", Leading the DBS 2.0 Era!

Scan the QR code to watch the wonderful recorded broadcast

On August 8, 2025, during "The 22nd Annual Meeting of the Chinese Neurosurgical Society" (CNS 2025), SceneRay held the "Multi-Circuit Neuromodulation in the DBS 2.0 Era & Product Launch Press Conference of SR1384 System", arousing widespread concern. At the conference, SceneRay officially launched the SR1384 System (SR1384 Y-type Extension), marking the entry of deep brain stimulation (DBS) technology into the DBS 2.0 era and opening up a new exploration of multi-circuit neuromodulation.

DBS technology, as a key treatment means in the field of neuroscience, has always played an important role in improving the quality of life (QOL) of patients. However, the traditional DBS technology still has certain limitations in the treatment of some complex diseases. SceneRay has long been committed to the exploration of brain science and has always regarded efficacy improvement as its core objective. The SR1384 System launched this time is another great achievement made by SceneRay on the road to technological innovation.

Professor Shizhong Zhang from Zhujiang Hospital of Southern Medical University presided over the Product Launch Press Conference and delivered a speech. He said that "Over the past years, we have always been committed to optimizing the efficacy of DBS. Now, we have officially opened up a new chapter for efficacy improvement and entered the DBS 2.0 era of multi-circuit neuromodulation. In this era, we advocate free innovation of efficacy and free exploration of infinite possibilities, striving to achieve greater freedom of efficacy and make exploration break through existing boundaries. As we all know, the efficacy of DBS has always been the focus of neurosurgeons' attention. Especially in the presence of multiple symptoms, how to achieve the transformation from single-target to multi-target treatment and upgrade from fixed parameter mode to free programming mode has become the key to improving the efficacy. DBS 2.0 is redefining the upper limit of efficacy! Today, let's witness how the SR1384 System tailors individualized neural circuit solutions for each patient by providing clinicians with more space to choose and explore."

Mr. Yihua Ning, Chairman of SceneRay, said in his presentation titled "DBS 2.0 Era: Multi-Circuit Neuromodulation" that neuromodulation technology made the treatment of Parkinson's disease (PD) enter a new phase 30 years ago, but previous technological improvements mostly focused on single-target treatment and single-circuit neuromodulation. Since neurological diseases often involve multi-circuit injuries, single-target neuromodulation has multiple limitations. For example, it cannot resolve the problems of freezing of gait (FOG), long-term tolerance, and efficacy decline. The launch of the SR1384 System marks the beginning of the DBS 2.0 era for multi-circuit neuromodulation. Relying on multi-circuit neuromodulation, it can provide a new treatment idea for various diseases. Combined with visualized programming, it will break through the ceiling of efficacy. All in all, SceneRay looks forward to cooperating with various experts to lead the development of DBS technology.

Professor Wanhai Ding from Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University said in his presentation titled "DBS 2.0 Era: STN + NAc Dual-Target Treatment of Parkinson's Disease Complicated with Mental Disorders" that about 50% of PD patients are complicated with mental disorders such as anxiety and depression, but anti-PD drugs + antipsychotics have contradictions and will affect the treatment effect. The 8-Contact Rechargeable Deep Brain Stimulation System is available for a "4 + 4" mode, in which 4 contacts are placed in the subthalamus nucleus (STN) to alleviate dyskinesia, and the other 4 contacts are placed in the anterior limb of the internal capsule and the nucleus accumbens (NAc) to modulate neural circuits, thus achieving dual-target combination treatment. Clinical cases have shown that this treatment regimen can significantly lower the score of mental symptoms, reduce hallucinations and delusions, and improve movement disorders and mental disorders simultaneously through one surgery.

Professor Xiaowu Hu from Shanghai Donglei Brain Hospital made a presentation titled "STN + GPi Dual-target Treatment of Movement Disorders". The adapter of the extension marketed this time has an ingenious design and great clinical significance. In the selection of targets, STN and globus pallidus internus (GPi) have complementary functions. Therefore, the effect of STN + GPi dual-target treatment of movement disorders is "1 + 1 > 1". With flexible extension, smaller screw shell, and low volume and weight of implantable pulse generator (IPG), the new equipment is more convenient for surgical operations. Based on the cases shared, such as PD patients, dystonia patients, and other patients, "1 IPG + 4 electrodes" dual-target stimulation is available for self-contrast, can achieve an ideal effect and bring convenience to doctors, has controllable risks, and can complete the treatment in one step.

At the Product Launch Press Conference, Professor Shizhong Zhang, Mr. Yihua Ning, Professor Wanhai Ding, and Professor Xiaowu Hu took the stage and pressed the Start Button together, marking the official launch of SceneRay's SR1384 System (SR1384 Y-type Extension). This milestone event has not only heralded the advent of the DBS 2.0 era but also realized more flexible neural circuit intervention through the design innovation of the extension, opening up a new path for the innovation of treatment modes for neurological diseases and the improvement of patient efficacy.

In the future, SceneRay will continue to focus on the field of neuroscience, adhere to the principle of prioritizing efficacy, and join hands with medical peers to break through the boundary of neuromodulation technology, promoting precision and individualized treatment of global patients with neurological diseases, and enabling more patients to benefit from China's innovative medical technology. Let's expect that SceneRay's SR1384 System will shine brightly in clinical application, bring hope to more patients, and lead neuroscience towards a broader exploration journey.